Champions Oncology, Inc.
CSBR
$8.17
-$0.68-7.68%
| 01/31/2025 | 10/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 26.32% | -4.07% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 26.32% | -4.07% | |||
| Cost of Revenue | -10.92% | 5.03% | |||
| Gross Profit | 71.95% | -13.28% | |||
| SG&A Expenses | 15.49% | -13.46% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.70% | 0.20% | |||
| Operating Income | 514.62% | -44.92% | |||
| Income Before Tax | 511.37% | -44.60% | |||
| Income Tax Expenses | 109.09% | -47.62% | |||
| Earnings from Continuing Operations | 517.45% | -44.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 517.45% | -44.55% | |||
| EBIT | 514.62% | -44.92% | |||
| EBITDA | 332.98% | -36.39% | |||
| EPS Basic | 512.13% | -44.51% | |||
| Normalized Basic EPS | 506.18% | -44.54% | |||
| EPS Diluted | 520.00% | -44.44% | |||
| Normalized Diluted EPS | 495.76% | -44.44% | |||
| Average Basic Shares Outstanding | 0.79% | 0.00% | |||
| Average Diluted Shares Outstanding | 2.48% | -0.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
